A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2332-2336

  De Oliveira, Fábio Morato ^a,b   De Carvalho Palma, Leonardo ^a,b   Falcão, Roberto Passetto ^a,b   Simões, Belinda Pinto ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute of Science and Technology in Stem Cell and Cell Therapy   (Brazil)

Author keywords

CML; Cytogenetic; dic(7; 12)(p12.21; p12.2); Lymphoid blast crisis; SKY

Indexed keywords

BCR ABL PROTEIN; CD19 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DASATINIB; HLA DR ANTIGEN; IMATINIB; METHOTREXATE;

ADULT; ARTICLE; BLAST CELL CRISIS; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPING; LYMPHOID BLAST CRISIS; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT RESPONSE;

ADULT; BLAST CRISIS; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 7; HOMEODOMAIN PROTEINS; HUMANS; ISOCHROMOSOMES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PHILADELPHIA CHROMOSOME; TRANSLOCATION, GENETIC;

EID: 84867979681     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0142-3     Document Type: Article

References (22)

1. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-22.
2. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-64.
3. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94.
4. Hagemeijer A. Chromosomal abnormalities in CML. Baillieres Clin Haematol. 1987;1:963-81.
5. Zhao L, Khan Z, Hayes L, Glassman A. Interphase fluorescence in situ hybridization analysis: a study using centromeric probes 7, 8 and 12. Ann Clin Lab Sci. 1998;28:51-6.
6. Ilaria RL Jr. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology Am Soc Hematol Educ Program. 2005;188-94.
7. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, et al. Randomized comparison of interferon-alpha with bussulphan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84(12):4064-77.
8. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosom Cancer. 1991;3(1):1-7.
9. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN (2009): an international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: Karger; 2009.
10. Wang Y, Hopwood VL, Hu P, Lennon A, Osterberger J, Glassman A. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia. Cancer Genet Cytogenet. 2004;153(1):53-6.
11. Watmore AE, Potter AM, Sokol RJ, Wood JK. Value of cytogenetic studies in prediction of acute phase CML. Cancer Genet Cytogenet. 1985;14(3-4):293-301.
12. Swolin B, Weinfeld A, Westin J, Waldenström J, Magnusson B. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet. 1985;18(1):65-79.
13. Schröck E, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996;273:494-7.
14. Veldman T, Vignon C, Schrock E, Rowley JD, Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet. 1997;15:406-10.
15. Oliveira FM, Lucena-Araújo AR, Leite-Cueva SD, Santos GA, Rego EM, Falcão RP. Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. Cancer Genet Cytogenet. 2010;198(1):62-5.
16. Oliveira FM, Falcão RP, de Figueiredo Pontes LL, Simões BP, Tone LG. Insertion (15;14)(q22;q13q32) in a case of Ph+ ALL. Cancer Genet Cytogenet. 2008;185(1):65-7.
17. Johnson E, Cotter FE. Monosomy 7 and 7q associated with myeloid malignancy. Blood Rev. 1997;11:46-55.
18. Lam DH, Aplan PD. NUP98 gene fusions in hematologic malignancies. Leukemia. 2001;15:1689-95.
19. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol. 2005;15:162-74.
20. Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ, Wainscoat JS. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood. 2000;96(1):358-61.
21. Boultwood J, Fidler C, Shepherd P, Watkins F, Snowball J, Haynes S, Kusec R, Gaiger A, Littlewood TJ, Peniket AJ, Wainscoat JS. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol. 1999;61(1):5-9.
22. Keller G, Brassat U, Braig M, Heim D, Wege H, Brümmendorf TH. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematol Oncol. 2009;27(3):123-9.